Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
Home About Us Product Pipeline News Investors Contacts Careers

News

Recent Press Releases Archives

Recent Press Releases

2017 News Releases

December 14, 2017 - Puma Biotechnology Added to NASDAQ Biotechnology Index
Read

December 13, 2017 - Puma Biotechnology Announces Meeting of Scientific Advisory Group on Oncology in Europe to Review Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

December 12, 2017 - Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
Read

December 11, 2017 - Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings
Patent Claims for Extended Adjuvant Treatment Upheld
Read

December 6, 2017 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
Read

November 22, 2017 - Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia
Read

November 13, 2017 - Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology
Data Demonstrates Continued Benefit from Neratinib after 5 years in Extended Adjuvant HER2-Positive Breast Cancer
Read

November 9, 2017 - Puma Biotechnology Reports Third Quarter 2017 Financial Results
Results include the initial sales of NERLYNX® in the U.S.
Read

November 8, 2017 - Puma Biotechnology to Present at Stifel Healthcare Conference
Read

November 2, 2017 - Puma Biotechnology Secures $100 Million Term Loan from Silicon Valley Bank and Oxford Finance
Read

October 31, 2017 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read

October 26, 2017 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read

September 18, 2017 - Puma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference
Read

September 8, 2017 - Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congress
Data Demonstrates Continued Benefit from Neratinib after 5 years
Read

August 31, 2017 - Puma Biotechnology to Participate in Panel Discussion at Citi’s Biotech Conference
Read

August 30, 2017 - Puma Biotechnology Announces Publication of Abstracts for ESMO 2017
Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer
Read

August 25, 2017 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

August 9, 2017 - Puma Biotechnology Reports Second Quarter 2017 Financial Results
Read

August 2, 2017 - Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP)
Read

July 31, 2017 - Puma Announces Availability of NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in the United States
Read

July 17, 2017 - U.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

July 6, 2017 - Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial
Read

June 3, 2017 - Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting
Read

May 31, 2017 - Puma Biotechnology to Present at the Jefferies 2017 Healthcare Conference
Read

May 24, 2017 - Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib
Read

May 22, 2017 - Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting
Read

May 17, 2017 - Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting
Read

May 10, 2017 - Puma Biotechnology Reports First Quarter 2017 Financial Results
Read

May 9, 2017 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2017 Health Care Conference
Read

April 17, 2017 - Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

April 4, 2017 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting
Read

April 2, 2017 - Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting
Read

April 2, 2017 - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting
Read

April 2, 2017 - Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers
Caligor Opco LLC to Provide Regulatory and Logistical Management
Read

March 2, 2017 - Puma Biotechnology to Present at Cowen’s Health Care Conference
Read

March 1, 2017 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017
Read

March 1, 2017 - Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272
Read

March 1, 2017 - Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results
Read

February 14, 2017 - Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference
Read

February 8, 2017 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference
Read

January 6, 2017 - Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients
Read

January 3, 2017 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference
Read




Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax